Newsfiscal.ai
Actuate Therapeutics Presents Preclinical Data for Elraglusib in Melanoma Models
· Published
Article summary
Actuate Therapeutics announced new preclinical data demonstrating the antitumor and immune activation activity of its oral elraglusib tablet in advanced melanoma models at the ENA 2026 symposium.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…